The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Metabolomics in myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, talks on metabolomics in multiple myeloma, focusing on how our understanding of the normal biology of plasma cells has led to a better understanding of mechanisms of action of certain drugs, such as proteasome inhibitors. Immunomodulatory drugs (IMiDs) also participate in the disruption of protein metabolism; studies have shown that IMiDs can interfere with the process of detoxifying plasma cells. Dr Fonseca believes that a complete understanding of the metabolic processes will allow for more precise forms of treatment for myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
